1. Generics Bulletin
  2. >>Business
  3. >>Strategy

Strides Targets $200m-$400m From Injectables

Biosimilars In Development Include Insulin Glargine And Lispro

 
• By Vibha Ravi

Strides has set a sales target of $200m-$400m for Stelis’ generic injectables business in two to four years as part of its plan to reach $800m in total revenues in four years. Meanwhile, Stelis’ Rh-teriparatide for osteoporosis and sodium hyaluronate for osteoarthritis await Phase III incremental studies in the US.

Growth
Strides Chalks Stelis' Growth Strategy • Source: Shutterstock

Strides Pharma Science Ltd. (formerly known as Strides Shasun Ltd.) has set a revenue target of $200-400m over the next two to four years for the injectables business housed under Stelis Biopharma Pvt Ltd., a company in which it is a majority shareholder.

In a presentation to investors on 5 December outlining its strategy to get to $800m in group sales over the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Stada And Bio-Thera Add To Biosimilars Alliance With Tocilizumab

 
• By Dave Wallace

Stada and Bio-Thera Solutions have added another product to their biosimilars partnership, with the Chinese developer’s tocilizumab rival to Roche’s RoActemra set to be marketed by the German giant in Europe.

‘It Validates Adalvo‘ – CEO Anil Okay Talks EQT Takeover

 
• By Dave Wallace

In the wake of a major transaction that saw private-equity firm EQT take control of Alvo group B2B business Adalvo, CEO Anil Okay talks to Generics Bulletin about what the deal means for Adalvo and how it is planning to expand in future.

Building A Biosimilar ‘Launch Machine’ For MENA – MS Pharma CEO Sets Out Strategy

 
• By Dave Wallace

MENA specialist MS Pharma has been building up a portfolio of licensed biosimilars in recent years to build on its generics roots, seeking a first-mover advantage in key markets as well as benefiting from local manufacturing operations. Chief executive Kalle Känd sets out the firm’s strategy.

Aeon Expects Imminent Data On Botox Biosimilar

 
• By Dave Wallace

Aeon Biopharma says it expects to complete primary structure and select functional analyses for its ABP-450 proposed biosimilar to Botox by the end of the current quarter, ahead of a meeting with the FDA in late 2025 to discuss next steps.

More from Business

ANI Raises Guidance Once More But Admits Generics Sales Will Soften In H2

 
• By Dean Rudge

ANI insisted that it would continue to invest in Generics R&D to keep up a cadence of launches, following another strong quarter on the back of generic prucalopride and its Cortrophin Gel.

Biocon Alludes To Double-Digit Generic Growth Despite Limited Revlimid Rival Sales Drying Up

 
• By Urtė Fultinavičiūtė

It was fun while it lasted for Biocon, but now its generic Revlimid waits on the sidelines until the unlimited market opens in 2026. The biosimilars business is set on a growth path, but its $1.15bn debt has left investors wondering whether the Viatris acquisition met its goals.

Natco Pharma Sues Novo Nordisk In Delhi Over Semaglutide IP

 
• By Dean Rudge

In the Delhi High Court, Natco Pharma has initiated proceedings against Novo Nordisk, requesting a ruling of non-infringement regarding a patent tied to semaglutide, the ingredient in the Danish originator’s Ozempic and Wegovy brands.